Relay Therapeutics (RLAY) Net Margin (2021 - 2026)
Relay Therapeutics' (RLAY) quarterly Net Margin came in at 2637.57% in Q1 2026, down 162224.0% year-on-year from N/an in Q1 2025, and down 426.24% on a QoQ basis from 501.21% in Q4 2025.
Relay Therapeutics (RLAY) Net Margin (2021 - 2026) Analysis & Trends
Relay Therapeutics (RLAY) has 6 years of Net Margin data on file, last reported at 2637.57% in Q1 2026.
- On a quarterly basis, Net Margin fell 162224.0% year-over-year to 2637.57% in Q1 2026; TTM through Mar 2026 was 2457.76%, a 724125.0% increase from a year earlier, with the FY2025 full-year figure at 4924.91%, up 276622.0% from the prior year.
- Net Margin for Q1 2026 stood at 2637.57%, down from 501.21% in the prior quarter.
- Over the last five years, Net Margin for RLAY reached as high as 8926900.0% in Q4 2023 and fell as low as 94462.18% in Q2 2023.
- Historically, Net Margin has averaged 667142.37% across 5 years, with a median of 10927.62% in 2025.
- On a YoY basis, Net Margin climbed as much as 895656719 bps in 2023 and fell as far as 6914575 bps in 2023.
- Year by year, Net Margin stood at 29667.19% in 2022, then soared by 30190 bps to 8926900.0% in 2023, then sank by 100 bps to 826.5% in 2024, then jumped by 39 bps to 501.21% in 2025, then plunged by 426 bps to 2637.57% in 2026.
- Per Business Quant data, the three most recent Net Margin figures were 2637.57% in Q1 2026, 501.21% in Q4 2025, and 10927.62% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | - |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 15.02% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 34.53% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 20.17% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 28.20% |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | - |
| 10 | Relay Therapeutics | 3.31 Bn | 3.31 Bn | - | -2,637.57% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2,637.57% |
| Dec 31, 2025 | -501.21% |
| Jun 30, 2025 | -10,927.62% |
| Mar 31, 2025 | -1,015.33% |
| Mar 31, 2024 | -826.50% |
| Dec 31, 2023 | 8,926,900.00% |
| Sep 30, 2023 | -294.69% |
| Jun 30, 2023 | -94,462.18% |
| Mar 31, 2023 | -44,500.44% |
| Dec 31, 2022 | -29,667.19% |
| Sep 30, 2022 | -24,790.41% |
| Jun 30, 2022 | -25,316.44% |
| Mar 31, 2022 | -19,109.55% |
| Dec 31, 2021 | -11,897.00% |
| Sep 30, 2021 | -9,134.08% |
| Jun 30, 2021 | -22,954.50% |
| Mar 31, 2021 | -4,434.77% |